UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.453

Sortiert nach

Rural-Urban Disparities in Access to Medicaid-Contracted Pharmacies in Washington State, 2017

Preventing chronic disease, 2020-08, Vol.17, p.E92-E92, Article 200066

2020

Volltextzugriff (PDF)

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6009-6009

2017

Volltextzugriff (PDF)

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3502-3502

2016

Volltextzugriff (PDF)

From Second Language to Third Language Learning: Exploring a Dual-Motivation System among Multilinguals

Australian review of applied linguistics, 2018, Vol.41 (1), p.61-90

2018

Volltextzugriff (PDF)

Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14032-e14032

2019

Volltextzugriff (PDF)

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-11, Vol.26 (11), p.925-e1918

2021

Volltextzugriff (PDF)

Maximally Entangled State in Pseudo-Telepathy Games

Computing with New Resources, p.200-207

Volltextzugriff (PDF)

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2514-2514

2019

Volltextzugriff (PDF)

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3056-3056

2020

Volltextzugriff (PDF)

A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.6034-6034

2017

Volltextzugriff (PDF)

Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e17506-e17506

2017

Volltextzugriff (PDF)

Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.6025-6025

2018

Volltextzugriff (PDF)

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS3087-TPS3087

2015

Volltextzugriff (PDF)

Phase II trial of eribulin for recurrent or metastatic salivary gland cancers

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6095-6095

2016

Volltextzugriff (PDF)

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma

The Laryngoscope, 2017-07, Vol.127 (7), p.1583-1588

2017

Volltextzugriff (PDF)

Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3002-3002

2016

Volltextzugriff (PDF)

Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.6048-6048

2016

Volltextzugriff (PDF)

Reported childhood sexual abuse and eating-disordered cognitions and behaviors

Child abuse & neglect, 2005-04, Vol.29 (4), p.375-382

2005

Volltextzugriff (PDF)

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX) and the PK of RAM as monotherapy in patients (pts) with advanced malignant solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e13554-e13554

2014

Volltextzugriff (PDF)

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8022-8022

2014

Volltextzugriff (PDF)

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e13539-e13539

2014

Volltextzugriff (PDF)

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8023-8023

2014

Volltextzugriff (PDF)

Cetuximab concurrent with postoperative radiation (Cet-XRT) in poor risk patients with resected squamous cell carcinomas of the head and neck (SCCHN)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e17037-e17037

2015

Volltextzugriff (PDF)

Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e17065-e17065

2015

Volltextzugriff (PDF)

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8028-8028

2015

Volltextzugriff (PDF)

1 – 25 von 1.453

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.261)
Mit Volltextzugriff
(1.349)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(741)
Life Sciences & Biomedicine
(608)
Humans
(470)
Female
(256)
Male
(228)
Animals
(168)
Biological And Medical Sciences
(154)
Middle Aged
(119)
Adult
(115)
Medical Sciences
(114)
Mice
(83)
Physical Sciences
(83)
Social Sciences
(82)
Aged
(78)
Science & Technology - Other Topics
(67)
Biochemistry & Molecular Biology
(64)
Technology
(64)
Cell Biology
(62)
Adolescent
(60)
Chemistry
(60)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Rural-Urban Disparities in Access to Medicaid-Contracted Pharmacies in Washington State, 2017

Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC)

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)

From Second Language to Third Language Learning: Exploring a Dual-Motivation System among Multilinguals

Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response

First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors

Maximally Entangled State in Pseudo-Telepathy Games

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy

A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy

A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC)

Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution

Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC)

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies

Phase II trial of eribulin for recurrent or metastatic salivary gland cancers

Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma

Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors

Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial

Reported childhood sexual abuse and eating-disordered cognitions and behaviors

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX) and the PK of RAM as monotherapy in patients (pts) with advanced malignant solid tumors

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC

Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results

Cetuximab concurrent with postoperative radiation (Cet-XRT) in poor risk patients with resected squamous cell carcinomas of the head and neck (SCCHN)

Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP)

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC)

Suchergebnisse filtern